The prevalence and related factors of fatigue in patients with COPD: a systematic review
- PMID: 33853886
- PMCID: PMC9489028
- DOI: 10.1183/16000617.0298-2020
The prevalence and related factors of fatigue in patients with COPD: a systematic review
Abstract
Background: Fatigue is a distressing symptom in patients with COPD. Little is known about the factors that contribute to fatigue in COPD. This review summarises existing knowledge on the prevalence of fatigue, factors related to fatigue and the instruments most commonly used to assess fatigue in COPD.
Methods: Pubmed, PsycINFO, EMBASE, Cochrane and CINAHL databases were searched for studies from inception up to 7 January 2020 using the medical subject headings "COPD" and "Fatigue". Studies were reviewed in accordance with PRISMA guidelines.
Results: 196 studies were evaluated. The prevalence of fatigue ranged from 17-95%. Age (r=-0.23 to r=0.27), sex (r=0.11), marital status (r=-0.096), dyspnoea (r=0.13 to r=0.78), forced expiatory volume in 1 s % predicted (r=-0.55 to r=-0.076), number of exacerbations (r=0.27 to r=0.38), number of comorbidities (r=0.10), number of medications (r=0.35), anxiety (r=0.36 to r=0.61), depression (r=0.41 to r=0.66), muscle strength (r=-0.78 to r=-0.45), functional capacity (r=-0.77 to r=-0.14) and quality of life (r=0.48 to r=0.77) showed significant associations with fatigue.
Conclusions: Fatigue is a prevalent symptom in patients with COPD. Multiple physical and psychological factors seem to be associated with fatigue. Future studies are needed to evaluate these underlying factors in integral analyses in samples of patients with COPD.
©The authors 2021.
Conflict of interest statement
Conflict of interest: Z. Ebadi has nothing to disclose. Conflict of interest: M.J. Goërtz has nothing to disclose. Conflict of interest: M. Van Herck has nothing to disclose. Conflict of interest: D.A.J. Janssen reports personal fees from Novartis, Boehringer Ingelheim and AstraZeneca, outside the submitted work. Conflict of interest: M.A. Spruit reports grants from Netherlands Lung Foundation, Stichting Astma Bestrijding, Boehringer Ingelheim and AstraZeneca, during the conduct of the study; and personal fees from Boehringer Ingelheim and AstraZeneca, outside the submitted work. Conflict of interest: C. Burtin has nothing to disclose. Conflict of interest: M.S.Y. Thong has nothing to disclose. Conflict of interest: J. Muris has nothing to disclose. Conflict of interest: J. Otker has nothing to disclose. Conflict of interest: M. Looijmans has nothing to disclose. Conflict of interest: C. Vlasblom has nothing to disclose. Conflict of interest: J. Bastiaansen has nothing to disclose. Conflict of interest: J. Prins has nothing to disclose. Conflict of interest: E.F.M. Wouters has nothing to disclose. Conflict of interest: J.H. Vercoulen has nothing to disclose. Conflict of interest: J.B. Peters has nothing to disclose.
Figures


Similar articles
-
Telehealth interventions: remote monitoring and consultations for people with chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2021 Jul 20;7(7):CD013196. doi: 10.1002/14651858.CD013196.pub2. Cochrane Database Syst Rev. 2021. PMID: 34693988 Free PMC article.
-
Interventions to improve adherence to pharmacological therapy for chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2021 Sep 8;9(9):CD013381. doi: 10.1002/14651858.CD013381.pub2. Cochrane Database Syst Rev. 2021. PMID: 34496032 Free PMC article.
-
Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care.Cochrane Database Syst Rev. 2022 May 6;5(5):CD012652. doi: 10.1002/14651858.CD012652.pub2. Cochrane Database Syst Rev. 2022. PMID: 35514131 Free PMC article.
-
Self-management interventions for people with chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2022 Jan 10;1(1):CD002990. doi: 10.1002/14651858.CD002990.pub4. Cochrane Database Syst Rev. 2022. PMID: 35001366 Free PMC article.
-
Chronic non-invasive ventilation for chronic obstructive pulmonary disease.Cochrane Database Syst Rev. 2021 Aug 9;8(8):CD002878. doi: 10.1002/14651858.CD002878.pub3. Cochrane Database Syst Rev. 2021. PMID: 34368950 Free PMC article.
Cited by
-
Symptom burden and its associations with clinical characteristics in patients with COPD: a clustering approach.ERJ Open Res. 2024 Aug 5;10(4):01052-2023. doi: 10.1183/23120541.01052-2023. eCollection 2024 Jul. ERJ Open Res. 2024. PMID: 39104954 Free PMC article.
-
Impact of chronic obstructive pulmonary disease on lung cancer symptom burden: a population-based study in Ontario, Canada.Transl Lung Cancer Res. 2023 Nov 30;12(11):2260-2274. doi: 10.21037/tlcr-23-560. Epub 2023 Nov 28. Transl Lung Cancer Res. 2023. PMID: 38090519 Free PMC article.
-
Extending the EQ-5D: the case for a complementary set of 4 psycho-social dimensions.Qual Life Res. 2023 Feb;32(2):495-505. doi: 10.1007/s11136-022-03243-7. Epub 2022 Sep 20. Qual Life Res. 2023. PMID: 36125601 Free PMC article.
-
Which breathlessness dimensions associate most strongly with fatigue?-The population-based VASCOL study of elderly men.PLoS One. 2023 Dec 20;18(12):e0296016. doi: 10.1371/journal.pone.0296016. eCollection 2023. PLoS One. 2023. PMID: 38117831 Free PMC article.
-
Are Fatigue and Pain Overlooked in Subjects with Stable Chronic Obstructive Pulmonary Disease?Diagnostics (Basel). 2021 Nov 2;11(11):2029. doi: 10.3390/diagnostics11112029. Diagnostics (Basel). 2021. PMID: 34829376 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical